Danish Lundbeck’s Brexpiprazole Could Reach U.S. Market In 2015
This article was originally published in The Pink Sheet Daily
Executive Summary
But the CNS disease specialist also expects the continuing loss of marketing exclusivity on key products and product launch costs to hold back revenue growth and profits in 2015 that will not be fully compensated by sales from multiple new product launches around the world.